亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

武漢楷倫化學新材料有限公司銷售部  

埃索美拉唑鈉和埃索美拉唑,埃索美拉唑鎂,比馬前列素,普樂沙福及其中間體,普拉格雷

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:吳桐
  • 電話:027-88395796
  • 郵件:kailunchem@126.com
  • 傳真:027-88735683
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 達比加群酯中間體42288-26-6,212322-56-0
達比加群酯中間體42288-26-6,212322-56-0
單價 面議對比
詢價 暫無
發貨 湖北武漢市付款后3天內
庫存 100公斤起訂1公斤
品牌 楷倫
型號 42288-26-6,212322-56-0
規格 42288-26-6,212322-56-0
過期 長期有效
更新 2014-05-29 14:26
 
詳細信息
 3-[(3-氨基-4-甲基氨基苯甲酰)吡啶-2-基氨基]丙酸乙酯

CAS:212322-56-0

英文名:Ethyl 3-(3-amino-4-(methylamino)-N-(pyridin-2-yl)benzamido)propanoate

外觀:黃色至淺棕色粉末

純度:99%

總雜:≤2.0%

單雜:≤0.5%

達比加群酯中間體

N-(4-禁發 氰 劇毒產品基苯基)甘氨酸

英文名:2-(4-cyanophenylamino)acetic acid

CAS:42288-26-6

外觀:白色至類白色粉末

純度:99%

達比加群酯中間體

©2025 武漢楷倫化學新材料有限公司銷售部 版權所有   技術支持:化工網   訪問量:10058  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |